Ocular Hypertension News and Research

RSS

Amakem backs new Chair of Ophthalmology Translational Research at KU Leuven

Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has sponsored a new Chair of Ophthalmology Translational Research at the Catholic University Leuven (KU Leuven), Belgium.

8 Apr 2013

Sucampo launches RESCULA Eye Drops in the U.S.

Sucampo Pharmaceuticals, Inc. announced that RESCULA Eye Drops had been launched in the U.S. market.

21 Feb 2013

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Sucampo Pharmaceuticals, Inc. today announced that RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% is now available by prescription across the United States. The U.S. Food and Drug Administration (FDA) approved a sNDA for RESCULA for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension on December 7, 2012.

19 Feb 2013

Glaucoma likely to end in visual impairment

Visual impairment at the end of life is highly likely to occur in patients with glaucoma, show Dutch study results.

2 Jan 2013

Only assess glaucoma drug efficacy after multiple testing

Intraocular pressure measurements may be insufficient to determine treatment effectiveness, even when repeated multiple times, show study results.

30 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL.

2 Nov 2012

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.

27 Sep 2012

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.

21 Aug 2012

Ocular Therapeutix announces results from sustained release OTX-TP1 study on glaucoma

Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.

24 Jul 2012

Glaucoma monitoring important in corneal dystrophy

The prevalence of glaucoma and/or ocular hypertension is more frequent in individuals with severe Fuchs’ endothelial corneal dystrophy than those without the condition, suggesting the importance of glaucoma screening in such patients, suggest US researchers.

18 Jul 2012

Daily IOP changes undermine measurement, medication

Day-to-day variability significantly undermines the precision of intraocular pressure measurement and the estimation of medication effectiveness in glaucoma patients, report researchers.

10 Jul 2012

Ocular Therapeutix initiates travoprost-loaded punctum plug trial in glaucoma

Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.

5 May 2012

Positive results from Bausch + Lomb, NicOx BOL‑303259‑X phase 2b study on OAG

Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.

13 Mar 2012

FDA approves preservative-free drug for glaucoma

The U.S. Food and Drugs Administration (FDA) has approved tafluprost ophthalmic solution (Zioptan, Merck) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution for glaucoma.

15 Feb 2012

Merck's ZIOPTAN for reducing elevated IOP receives FDA approval

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has approved ZIOPTANTM (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution.

13 Feb 2012

Macular degeneration drug may cause increased IOP

Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye. It led to a retrospective study and findings that will be presented at the American Academy of Ophthalmology in Orlando.

24 Oct 2011

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost. In the study, non-preserved latanoprost was compared to Xalatan (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.

26 Sep 2011

HSS, pSivida enter orthopedic evaluation agreement

Drug delivery company pSivida Corp. today announced it has entered into an evaluation agreement with Hospital for Special Surgery (HSS), a world leader in orthopedics, rheumatology and rehabilitation, to investigate pSivida's drug delivery technologies in orthopedics.

17 Aug 2011

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension.

22 Jul 2011